Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Two-stage revision with 'StageOne™ Select Hip Cement Spacer' is used as treatment of periprosthetic hip joint infection. The aim is to evaluate complications and restoration the joint with the StageOne Select Spacer. From 2013 to 2018 twenty-nine StageOne Select Spacers was inserted. Data was obtained through medical records and radiographs. 3.5% dislocated the spacer, 6.9% sustained a femoral fracture, 6.9% got reinfected and 6.9% failed to control the infection. Leg length discrepancy was 1.5 mm (-4,25-5.25) and offset discrepancy was 4 mm (-0.5-9). The spacer shows promising results with a low reinfection and dislocation rate and allowance of restoration of the joint.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994726 | PMC |
http://dx.doi.org/10.1016/j.jor.2019.09.016 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!